XM does not provide services to residents of the United States of America.

US to spend $10 million to curb bird flu in farm workers, including seasonal flu vaccine push



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US to spend $10 million to curb bird flu in farm workers, including seasonal flu vaccine push</title></head><body>

By Leah Douglas and Julie Steenhuysen

July 30 (Reuters) -The U.S. Centers for Disease Control and Prevention said on Tuesday it plans to spend $10 million to curb farm worker bird flu infections, including $5 million for seasonal flu vaccines, as part of its efforts to avoid further spread and mutation of the virus.

The ongoing outbreak of bird flu has infected poultry flocks in nearly every state since 2022 and more than 170 dairy herds in 13 states since March, according to the U.S. Department of Agriculture.

Thirteen poultry and dairy farm workers have contracted the virus in Colorado, Michigan, and Texas, according to the CDC. Nine of those cases were detected in July among workers killing chickens at two poultry farms with bird flu in Colorado.

The risk to the general public from bird flu is still low, said CDC's principal director Nirav Shah on a call with reporters.

The agency will allocate $5 million to organizations including the National Center for Farmworker Health to educate and train workers on protecting themselves from bird flu, and another $5 million to providing seasonal flu shots to farm workers, Shah said.

The vaccine push could reduce the risk that workers become co-infected with the seasonal flu and bird flu at the same time, which could lead to flu virus mutations, Shah said.

"Preventing seasonal influenza for these workers, many of whom are also exposed to bird flu, may reduce risks of new strains of influenza emerging," he said.

The agency is hoping to vaccinate all of the nation's approximately 200,000 livestock workers, Shah said.






Reporting by Leah Douglas in Washington and Julie Steenhuysen in Chicago; additional reporting by Ahmed Aboulenein in Washington; Editing by Bill Berkrot

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.